JP4381978B2 - アザインドールキナーゼインヒビター - Google Patents

アザインドールキナーゼインヒビター Download PDF

Info

Publication number: JP4381978B2
Authority: JP; Japan
Prior art keywords: pyrrolo; methyl; substituted; fluoro; pyridin
Prior art date: 2002-07-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2004523591A

Other languages

English (en)

Japanese (ja)

Other versions

JP2005538990A (ja

Inventor

ラジーブ・ビデ

ルジャン・リュエル

カール・ティボー

アレクサンドル・ルルー

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-19

Filing date

2003-07-18

Publication date

2009-12-09

2003-07-18 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2005-12-22 Publication of JP2005538990A publication Critical patent/JP2005538990A/ja

2009-12-09 Application granted granted Critical

2009-12-09 Publication of JP4381978B2 publication Critical patent/JP4381978B2/ja

2023-07-18 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

0 *c(c(C(O*)=O)c1)c2[n]1N=CNC2=O Chemical compound *c(c(C(O*)=O)c1)c2[n]1N=CNC2=O 0.000 description 5
GFDXWAJWRTXLGX-UHFFFAOYSA-N CCc1c(C)nc(-c(c(C(C)C)c23)c[n]2ncnc3Nc(cnc2c3cc[nH]2)c3F)[o]1 Chemical compound CCc1c(C)nc(-c(c(C(C)C)c23)c[n]2ncnc3Nc(cnc2c3cc[nH]2)c3F)[o]1 GFDXWAJWRTXLGX-UHFFFAOYSA-N 0.000 description 1
KKFIQPYUIHVKBH-UHFFFAOYSA-N Cc(c(OCc1ccccc1)c1)c2[n]1ncnc2Oc(cnc1c2cc[nH]1)c2F Chemical compound Cc(c(OCc1ccccc1)c1)c2[n]1ncnc2Oc(cnc1c2cc[nH]1)c2F KKFIQPYUIHVKBH-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)

JP2004523591A 2002-07-19 2003-07-18 アザインドールキナーゼインヒビター Expired - Fee Related JP4381978B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39725602P	2002-07-19	2002-07-19
US44721303P	2003-02-13	2003-02-13
PCT/US2003/022554 WO2004009601A1 (en)	2002-07-19	2003-07-18	Azaindole kinase inhibitors

Publications (2)

Publication Number	Publication Date
JP2005538990A JP2005538990A (ja)	2005-12-22
JP4381978B2 true JP4381978B2 (ja)	2009-12-09

Family

ID=30773005

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2004523591A Expired - Fee Related JP4381978B2 (ja)	2002-07-19	2003-07-18	アザインドールキナーゼインヒビター
JP2004523256A Expired - Lifetime JP4361485B2 (ja)	2002-07-19	2003-07-18	キナーゼの新規インヒビター

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2004523256A Expired - Lifetime JP4361485B2 (ja)	2002-07-19	2003-07-18	キナーゼの新規インヒビター

Country Status (32)

Country	Link
US (6)	US6869952B2 (2)
EP (3)	EP1539763B1 (2)
JP (2)	JP4381978B2 (2)
KR (1)	KR100901939B1 (2)
CN (3)	CN101880283B (2)
AR (1)	AR040500A1 (2)
AT (2)	ATE537843T1 (2)
AU (2)	AU2003254088B2 (2)
BR (2)	BR0312801A (2)
CA (2)	CA2492665A1 (2)
CO (1)	CO5680407A2 (2)
CY (1)	CY1112628T1 (2)
DE (1)	DE60336732D1 (2)
DK (1)	DK1534290T3 (2)
ES (1)	ES2377963T3 (2)
GE (2)	GEP20074213B (2)
HR (2)	HRP20050059B8 (2)
IL (3)	IL166129A0 (2)
IS (2)	IS7646A (2)
MX (2)	MXPA05000715A (2)
MY (1)	MY134848A (2)
NO (2)	NO330132B1 (2)
NZ (1)	NZ537523A (2)
PE (1)	PE20040680A1 (2)
PL (2)	PL375352A1 (2)
PT (1)	PT1534290E (2)
RS (2)	RS20050041A (2)
RU (2)	RU2331642C2 (2)
SI (1)	SI1534290T1 (2)
TW (1)	TWI329112B (2)
UA (1)	UA82846C2 (2)
WO (2)	WO2004009601A1 (2)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999001124A1 (en) *	1996-12-03	1999-01-14	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
DE69734871D1 (de) *	1997-05-30	2006-01-19	St Microelectronics Srl	Verfahren zur Herstellung eines Germanium-implantierten bipolaren Heteroübergangtransistors
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
US6982265B1 (en) *	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) *	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) *	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
KR101025675B1 (ko) *	2002-04-23	2011-03-30	브리스톨-마이어스 스큅 컴퍼니	키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
JP2005529890A (ja)	2002-04-23	2005-10-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
TW200401638A (en) *	2002-06-20	2004-02-01	Bristol Myers Squibb Co	Heterocyclic inhibitors of kinases
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
DE60330407D1 (de) *	2002-08-23	2010-01-14	Sloan Kettering Inst Cancer	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
BRPI0407282A (pt)	2003-02-05	2006-01-31	Bristol Myers Squibb Co	Processo para preparação de inibidores de pirrolotriazina cinase
KR101254371B1 (ko)	2003-07-18	2013-05-02	암젠 프레몬트 인코포레이티드	간세포 성장인자에 결합하는 분리된 항체
US20060014741A1 (en) *	2003-12-12	2006-01-19	Dimarco John D	Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en)	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
US7459562B2 (en) *	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) *	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) *	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7498342B2 (en)	2004-06-17	2009-03-03	Plexxikon, Inc.	Compounds modulating c-kit activity
US7432373B2 (en) *	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) *	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
CN100577663C (zh) *	2004-06-28	2010-01-06	布里斯托尔-迈尔斯·斯奎布公司	稠合杂环型激酶抑制剂
US7173031B2 (en) *	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200600513A (en) *	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) *	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
SE0401790D0 (sv) *	2004-07-07	2004-07-07	Forskarpatent I Syd Ab	Tamoxifen response in pre- and postmenopausal breast cancer patients
US7504521B2 (en)	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en)	2004-08-12	2006-12-12	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en) *	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
MX2007006230A (es)	2004-11-30	2007-07-25	Amgen Inc	Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
DE102004060659A1 (de)	2004-12-15	2006-07-06	Lanxess Deutschland Gmbh	Neue substituierte 1H-Pyrrolo[2,3-b]pyridine und deren Herstellung
US7534882B2 (en)	2005-04-06	2009-05-19	Bristol-Myers Squibb Company	Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US20060257400A1 (en) *	2005-05-13	2006-11-16	Bristol-Myers Squibb Company	Combination therapy
AU2006272951A1 (en)	2005-05-17	2007-02-01	Plexxikon, Inc.	Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
US7393667B2 (en)	2005-05-31	2008-07-01	Bristol-Myers Squibb Company	Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US20060288309A1 (en) *	2005-06-16	2006-12-21	Cross Charles W Jr	Displaying available menu choices in a multimodal browser
CN102206216B (zh)	2005-06-22	2014-11-12	普莱希科公司	作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
US7405213B2 (en) *	2005-07-01	2008-07-29	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7442700B2 (en) *	2005-07-01	2008-10-28	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7402582B2 (en)	2005-07-01	2008-07-22	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
GB0517387D0 (en) *	2005-08-26	2005-10-05	Antisoma Res Ltd	Combinations for the treatment of cancer
EP2182078B1 (en)	2005-09-01	2012-02-01	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
WO2007038648A1 (en) *	2005-09-27	2007-04-05	Bristol-Myers Squibb Company	Crystalline forms of [(1r), 2s]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester
US7547782B2 (en) *	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
KR101461680B1 (ko)	2005-12-02	2014-11-19	바이엘 헬스케어 엘엘씨	과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US20080108664A1 (en)	2005-12-23	2008-05-08	Liu Belle B	Solid-state form of AMG 706 and pharmaceutical compositions thereof
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
ATE489380T1 (de)	2006-02-10	2010-12-15	Amgen Inc	Hydratformen von amg706
US8063208B2 (en)	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
CN101395158A (zh)	2006-03-07	2009-03-25	百时美施贵宝公司	可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物
AU2007240453B2 (en)	2006-04-21	2012-04-12	Bristol-Myers Squibb Company	Process for the preparation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester
US20080112888A1 (en)	2006-06-30	2008-05-15	Schering Corporation	Igfbp2 biomarker
HRP20140688T1 (hr) *	2006-07-07	2014-10-24	Bristol-Myers Squibb Company	Inhibitori piroltriazin kinaze
PE20080403A1 (es)	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
US7531539B2 (en) *	2006-08-09	2009-05-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7605160B2 (en) *	2006-08-09	2009-10-20	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
CL2007003158A1 (es) *	2006-11-02	2008-05-16	Astrazeneca Ab	Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2125781A2 (en)	2006-12-20	2009-12-02	Amgen Inc.	Substituted heterocycles and methods of use
WO2008079909A1 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2,3-b] pyridines as kinase modulators
AU2007336811A1 (en)	2006-12-21	2008-07-03	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
PE20081581A1 (es)	2006-12-21	2008-11-12	Plexxikon Inc	COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
ATE548364T1 (de) *	2007-01-05	2012-03-15	Bristol Myers Squibb Co	Aminopyrazolkinasehemmer
AU2008205252B2 (en)	2007-01-09	2013-02-21	Amgen Inc.	Bis-aryl amide derivatives useful for the treatment of cancer
CN101627116B (zh) *	2007-02-08	2013-07-10	科德克希思公司	酮还原酶及其用途
AU2008219166B2 (en)	2007-02-16	2013-05-16	Amgen Inc.	Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
WO2008127526A2 (en) *	2007-03-12	2008-10-23	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
KR20090128474A (ko)	2007-04-13	2009-12-15	브리스톨-마이어스 스큅 컴퍼니	혈관 내피 성장인자 수용체-2 조절제에 대한 감수성을 판정하기 위한 방법 및 바이오마커
CN101687874B (zh) *	2007-04-18	2013-01-30	百时美施贵宝公司	吡咯并三嗪激酶抑制剂
TW200902019A (en)	2007-04-26	2009-01-16	Ono Pharmaceutical Co	Dicyclic heterocyclic compound
JP2010533729A (ja)	2007-07-17	2010-10-28	プレキシコン，インコーポレーテッド	キナーゼ調節のための化合物と方法、及びそのための適応
ES2650224T3 (es)	2007-08-21	2018-01-17	Amgen, Inc.	Proteínas de unión al antígeno C-FMS humano
RU2010120674A (ru)	2007-10-22	2011-11-27	Шеринг Корпорейшн (US)	Полностью человеческие анти-vegf-антитела и способы их применения
WO2009126311A1 (en) *	2008-04-11	2009-10-15	The University Of Texas, M.D. Anderson Cancer Center	Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
AR071717A1 (es)	2008-05-13	2010-07-07	Array Biopharma Inc	Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
ES2539620T3 (es)	2008-12-19	2015-07-02	Cephalon, Inc.	Pirrolotriazina como inhibidor de ALK y de JAK2
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2401614A1 (en)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
KR101739994B1 (ko)	2009-04-03	2017-05-25	에프. 호프만-라 로슈 아게	프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
EP2483406A2 (en)	2009-09-30	2012-08-08	President and Fellows of Harvard College	Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2011044019A1 (en) *	2009-10-05	2011-04-14	Bristol-Myers Squibb Company	(R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES
NZ599866A (en)	2009-11-06	2014-09-26	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
US20120258940A1 (en)	2009-12-18	2012-10-11	Giordano Caponigro	Method for treating haematological cancers
US9180127B2 (en)	2009-12-29	2015-11-10	Dana-Farber Cancer Institute, Inc.	Type II Raf kinase inhibitors
US8691981B2 (en) *	2010-02-03	2014-04-08	Bristol-Myers Squibb Company	Crystalline forms of (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide
JP5093527B2 (ja) *	2010-02-10	2012-12-12	日本電気株式会社	複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路
WO2011161217A2 (en)	2010-06-23	2011-12-29	Palacký University in Olomouc	Targeting of vegfr2
WO2012006550A2 (en) *	2010-07-09	2012-01-12	Obetech Llc	Methods and compositions for treatment of lipogenic virus related conditions
US8338771B2 (en) *	2010-11-05	2012-12-25	Green Plus Co., Ltd.	Apparatus for tracking and condensing sunlight of sliding type
KR101911972B1 (ko)	2011-02-07	2018-10-25	플렉시콘 인코퍼레이티드	키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI558702B (zh)	2011-02-21	2016-11-21	普雷辛肯公司	醫藥活性物質的固態形式
CN103703000B (zh)	2011-03-23	2015-11-25	安姆根有限公司	Cdk4/6和flt3的稠合三环双重抑制剂
EP2702173A1 (en)	2011-04-25	2014-03-05	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US8921533B2 (en)	2011-07-25	2014-12-30	Chromatin Technologies	Glycosylated valproic acid analogs and uses thereof
US9745288B2 (en)	2011-08-16	2017-08-29	Indiana University Research And Technology Corporation	Compounds and methods for treating cancer by inhibiting the urokinase receptor
CA2856291C (en)	2011-11-17	2020-08-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
CN103450204B (zh)	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
US9724352B2 (en)	2012-05-31	2017-08-08	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN102675323B (zh) *	2012-06-01	2014-04-09	南京药石药物研发有限公司	吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
WO2014036022A1 (en)	2012-08-29	2014-03-06	Amgen Inc.	Quinazolinone compounds and derivatives thereof
CN103664957A (zh) *	2012-09-25	2014-03-26	杨子娇	一类治疗房角狭窄的化合物及其用途
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en)	2012-10-19	2018-06-19	Dana-Farber Cancer Institute, Inc.	Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en)	2012-10-19	2017-09-12	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
FR3000494B1 (fr) *	2012-12-28	2015-08-21	Oribase Pharma	Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
US9050345B2 (en)	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
CA2901267C (en)	2013-04-04	2021-01-19	Janssen Pharmaceutica Nv	Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
EP3670496A3 (en) *	2013-10-17	2020-09-30	Shionogi&Co., Ltd.	Acc2 inhibitors
US10047070B2 (en)	2013-10-18	2018-08-14	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3057955B1 (en)	2013-10-18	2018-04-11	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
CN104725381B (zh) *	2013-12-19	2018-04-10	南京圣和药业股份有限公司	生长因子受体抑制剂及其应用
US10017477B2 (en)	2014-04-23	2018-07-10	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
US9862688B2 (en)	2014-04-23	2018-01-09	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
AU2015371251B2 (en)	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
US11083755B2 (en)	2015-01-08	2021-08-10	The Board Of Trustees Of The Leland Stanford Junior University	Factors and cells that provide for induction of bone, bone marrow, and cartilage
HK1246645A1 (zh)	2015-03-27	2018-09-14	达纳-法伯癌症研究所股份有限公司	细胞周期蛋白依赖性激酶的抑制剂
US10702527B2 (en)	2015-06-12	2020-07-07	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
EP3347018B1 (en)	2015-09-09	2021-09-01	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
DK3356345T3 (da)	2015-09-30	2024-02-12	Max Planck Gesellschaft	Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
EP3424505A4 (en)	2016-03-04	2019-10-16	Taiho Pharmaceutical Co., Ltd.	PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
LT3450436T (lt)	2016-04-28	2022-09-12	Takeda Pharmaceutical Company Limited	Kondensuotas heterociklinis junginys
SG10201911076QA (en)	2016-12-16	2020-01-30	Cystic Fibrosis Found	Bycyclic heteroaryl derivatives as cftr potentiators
WO2018119183A2 (en)	2016-12-22	2018-06-28	Amgen Inc.	Kras g12c inhibitors and methods of using the same
CN110139865B (zh) *	2016-12-29	2022-02-18	石药集团中奇制药技术（石家庄）有限公司	Fgfr抑制剂
EA201992781A1 (ru)	2017-05-22	2020-04-01	Эмджен Инк.	Ингибиторы g12c kras и способы их применения
MA50077A (fr)	2017-09-08	2020-07-15	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
SG11202008435SA (en)	2018-03-19	2020-10-29	Taiho Pharmaceutical Co Ltd	Pharmaceutical composition including sodium alkyl sulfate
WO2019213516A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
ES2995514T3 (en)	2018-05-04	2025-02-10	Amgen Inc	Kras g12c inhibitors and methods of using the same
EP3790886B1 (en)	2018-05-10	2024-06-26	Amgen Inc.	Kras g12c inhibitors for the treatment of cancer
ES2938987T3 (es)	2018-06-01	2023-04-18	Amgen Inc	Inhibidores de KRAS G12c y métodos de uso de los mismos
US20190375749A1 (en)	2018-06-11	2019-12-12	Amgen Inc.	Kras g12c inhibitors and methods of using the same
ES3060664T3 (en)	2018-06-12	2026-03-27	Amgen Inc	Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
US12187701B2 (en)	2018-06-25	2025-01-07	Dana-Farber Cancer Institute, Inc.	Taire family kinase inhibitors and uses thereof
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US11053226B2 (en)	2018-11-19	2021-07-06	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
EP3898616B1 (en)	2018-12-20	2024-10-02	Amgen Inc.	Heteroaryl amides useful as kif18a inhibitors
WO2020132651A1 (en)	2018-12-20	2020-06-25	Amgen Inc.	Kif18a inhibitors
JP7676308B2 (ja)	2018-12-20	2025-05-14	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
TWI844602B (zh)	2018-12-20	2024-06-11	美商安進公司	Kif18a抑制劑
JPWO2020130125A1 (ja)	2018-12-21	2021-11-04	第一三共株式会社	抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
JP7660063B2 (ja)	2018-12-28	2025-04-10	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
WO2020180768A1 (en)	2019-03-01	2020-09-10	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
CN113727758A (zh)	2019-03-01	2021-11-30	锐新医药公司	双环杂环基化合物及其用途
AU2020274083B9 (en)	2019-05-13	2025-05-01	D.E. Shaw Research, Llc	FGFR inhibitors and methods of use thereof
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
NZ782284A (en)	2019-05-21	2024-11-29	Amgen Inc	Solid state forms
EP4007756B1 (en)	2019-08-02	2025-12-24	Amgen Inc.	Kif18a inhibitors
AU2020326627B2 (en)	2019-08-02	2026-01-29	Amgen Inc.	KIF18A inhibitors
WO2021026099A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
US12540129B2 (en)	2019-08-02	2026-02-03	Amgen Inc.	KIF18A inhibitors
EP4684786A3 (en)	2019-10-24	2026-04-08	Amgen Inc.	Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CN120699039A (zh)	2019-11-04	2025-09-26	锐新医药公司	Ras抑制剂
WO2021091956A1 (en)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Ras inhibitors
MX2022005359A (es)	2019-11-04	2022-06-02	Revolution Medicines Inc	Inhibidores de ras.
TW202128688A (zh)	2019-11-08	2021-08-01	美商銳新醫藥公司	雙環雜芳基化合物及其用途
WO2021094209A1 (en)	2019-11-12	2021-05-20	Bayer Aktiengesellschaft	Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021097207A1 (en)	2019-11-14	2021-05-20	Amgen Inc.	Improved synthesis of kras g12c inhibitor compound
JP2023501528A (ja)	2019-11-14	2023-01-18	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の改善された合成
AU2020387982B2 (en) *	2019-11-18	2023-08-03	Jumbo Drug Bank Co., Ltd.	Pyrrolotriazine compounds acting as MNK inhibitor
EP4065231A1 (en)	2019-11-27	2022-10-05	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
CN114929279A (zh)	2020-01-07	2022-08-19	锐新医药公司	Shp2抑制剂给药和治疗癌症的方法
IL299131A (en)	2020-06-18	2023-02-01	Revolution Medicines Inc	Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
MX2023002248A (es)	2020-09-03	2023-05-16	Revolution Medicines Inc	Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es)	2020-09-15	2023-04-05	Revolution Medicines Inc	Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
US20240051956A1 (en)	2020-12-22	2024-02-15	Qilu Regor Therapeutics Inc.	Sos1 inhibitors and uses thereof
WO2022235866A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
AU2022268962A1 (en)	2021-05-05	2023-12-14	Revolution Medicines, Inc.	Ras inhibitors for the treatment of cancer
CA3217393A1 (en)	2021-05-05	2022-11-10	Elena S. Koltun	Ras inhibitors
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
CA3237696A1 (en)	2021-11-08	2023-05-11	Progentos Therapeutics, Inc.	Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
TW202340214A (zh)	2021-12-17	2023-10-16	美商健臻公司	做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172858A1 (en)	2022-03-07	2023-09-14	Amgen Inc.	A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh)	2022-03-08	2024-12-13	锐新医药公司	用于治疗免疫难治性肺癌的方法
AU2023249795A1 (en) *	2022-04-08	2024-10-17	Shy Therapeutics, Llc	Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN119255825A (zh)	2022-05-24	2025-01-03	第一三共株式会社	抗-cdh6抗体-药物缀合物的剂量方案
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
AU2023358792A1 (en)	2022-10-14	2025-04-17	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024112656A1 (en) *	2022-11-21	2024-05-30	The Board Of Trustees Of The Leland Stanford Junior University	Use of a tyrosine kinase inhibitor for the treatment of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension
EP4687905A1 (en)	2023-03-30	2026-02-11	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
CN121263418A (zh)	2023-04-07	2026-01-02	锐新医药公司	大环ras抑制剂
KR20260005904A (ko)	2023-04-07	2026-01-12	레볼루션 메디슨즈, 인크.	매크로사이클릭 ras 억제제
KR20250172857A (ko)	2023-04-14	2025-12-09	레볼루션 메디슨즈, 인크.	Ras 억제제의 결정형
AU2024252105A1 (en)	2023-04-14	2025-10-16	Revolution Medicines, Inc.	Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024265078A1 (en)	2023-05-04	2025-12-11	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
CN116813526A (zh) *	2023-05-22	2023-09-29	四川省医学科学院·四川省人民医院	异吲哚啉酮类化合物、其制备方法及其应用
IL326136A (en)	2023-08-07	2026-03-01	Revolution Medicines Inc	RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
AU2024360599A1 (en) *	2023-10-10	2026-04-09	Shy Therapeutics, Llc	Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins
US20250154171A1 (en)	2023-10-12	2025-05-15	Revolution Medicines, Inc.	Ras inhibitors
TW202542151A (zh)	2023-12-22	2025-11-01	美商銳格醫藥有限公司	Ｓｏｓ１抑制劑及其用途
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
US20250375445A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026050446A1 (en)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Ras inhibitors
WO2026072904A2 (en)	2024-09-26	2026-04-02	Revolution Medicines, Inc.	Compositions and methods for treating lung cancer
CN121159543A (zh) *	2025-09-19	2025-12-19	合肥综合性国家科学中心大健康研究院	吡咯并[2,1-f][1,2,4]三嗪类化合物及其制备方法和应用、中间体、药物组合物和cGAS激动剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL107041A (en) *	1992-09-25	2000-02-17	Lilly Co Eli	Process for preparing omega(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo-6-¬2,3-d¾pyrimidin-5-YL)alkarylcarboxylic acids and N-(omega-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo¬2,3-d¾pyrimidin-5-YL)alk-aroyl-4-glutamic acids
US6191131B1 (en) *	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
DE60026297T2 (de) *	1999-05-21	2006-11-02	Bristol-Myers Squibb Co.	Pyrrolotriazin kinasehemmer
US6982265B1 (en) *	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
WO2001014378A1 (en) *	1999-08-23	2001-03-01	Shionogi & Co., Ltd.	PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES
GB0017256D0 (en) *	2000-07-13	2000-08-30	Merck Sharp & Dohme	Therapeutic agents
CA2416525A1 (en) *	2000-08-09	2002-02-14	Astrazeneca Ab	Indole, azaindole and indazole derivatives having vegf inhibiting activity
US6867300B2 (en) *	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
YU37903A (sh) *	2000-11-17	2006-05-25	Bristol-Myers Squibb Company	POSTUPCI LEČENJA STANJA POVEZANIH SA p38 KINAZOM I JEDINJENJA PIROLOTRIAZINA KOJA SE KORISTE KAO INHIBITORI KINAZE
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) *	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
JP2005529890A (ja) *	2002-04-23	2005-10-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
KR101025675B1 (ko) *	2002-04-23	2011-03-30	브리스톨-마이어스 스큅 컴퍼니	키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
TW200400034A (en) *	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200407143A (en) *	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
TWI272271B (en) *	2002-07-19	2007-02-01	Bristol Myers Squibb Co	Process for preparing certain pyrrolotriazine compounds
WO2004013145A1 (en) *	2002-08-02	2004-02-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200420565A (en) *	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
BRPI0407282A (pt) *	2003-02-05	2006-01-31	Bristol Myers Squibb Co	Processo para preparação de inibidores de pirrolotriazina cinase

2003
- 2003-07-14 TW TW092119165A patent/TWI329112B/zh not_active IP Right Cessation
- 2003-07-17 MY MYPI20032690A patent/MY134848A/en unknown
- 2003-07-18 CA CA002492665A patent/CA2492665A1/en not_active Abandoned
- 2003-07-18 EP EP03765754A patent/EP1539763B1/en not_active Expired - Lifetime
- 2003-07-18 RU RU2005104422/04A patent/RU2331642C2/ru active
- 2003-07-18 AU AU2003254088A patent/AU2003254088B2/en not_active Expired
- 2003-07-18 RS YUP-2005/0041A patent/RS20050041A/sr unknown
- 2003-07-18 US US10/623,171 patent/US6869952B2/en not_active Expired - Lifetime
- 2003-07-18 HR HRP20050059A patent/HRP20050059B8/hr not_active IP Right Cessation
- 2003-07-18 AU AU2003254017A patent/AU2003254017A1/en not_active Abandoned
- 2003-07-18 CN CN2010101428920A patent/CN101880283B/zh not_active Expired - Lifetime
- 2003-07-18 NZ NZ537523A patent/NZ537523A/en not_active IP Right Cessation
- 2003-07-18 CA CA002492804A patent/CA2492804C/en not_active Expired - Lifetime
- 2003-07-18 JP JP2004523591A patent/JP4381978B2/ja not_active Expired - Fee Related
- 2003-07-18 PL PL03375352A patent/PL375352A1/xx not_active Application Discontinuation
- 2003-07-18 JP JP2004523256A patent/JP4361485B2/ja not_active Expired - Lifetime
- 2003-07-18 MX MXPA05000715A patent/MXPA05000715A/es active IP Right Grant
- 2003-07-18 PL PL375389A patent/PL216663B1/pl unknown
- 2003-07-18 BR BRPI0312801-6A patent/BR0312801A/pt unknown
- 2003-07-18 EP EP10180960A patent/EP2280012A3/en not_active Withdrawn
- 2003-07-18 UA UAA200501515A patent/UA82846C2/uk unknown
- 2003-07-18 WO PCT/US2003/022554 patent/WO2004009601A1/en not_active Ceased
- 2003-07-18 GE GEAP8643A patent/GEP20074213B/en unknown
- 2003-07-18 BR BRPI0312940-3A patent/BRPI0312940B1/pt active IP Right Grant
- 2003-07-18 PT PT03765881T patent/PT1534290E/pt unknown
- 2003-07-18 MX MXPA05000716A patent/MXPA05000716A/es unknown
- 2003-07-18 KR KR1020087022726A patent/KR100901939B1/ko not_active Expired - Lifetime
- 2003-07-18 CN CNB038218208A patent/CN1315833C/zh not_active Expired - Fee Related
- 2003-07-18 HR HR20050058A patent/HRP20050058A2/hr not_active Application Discontinuation
- 2003-07-18 GE GEAP8644A patent/GEP20074124B/en unknown
- 2003-07-18 CN CN038219158A patent/CN1681508B/zh not_active Expired - Lifetime
- 2003-07-18 WO PCT/US2003/022826 patent/WO2004009784A2/en not_active Ceased
- 2003-07-18 RS YU20050042A patent/RS52325B/sr unknown
- 2003-07-18 EP EP03765881A patent/EP1534290B1/en not_active Expired - Lifetime
- 2003-07-18 US US10/622,593 patent/US6969717B2/en not_active Expired - Lifetime
- 2003-07-18 AT AT03765881T patent/ATE537843T1/de active
- 2003-07-18 ES ES03765881T patent/ES2377963T3/es not_active Expired - Lifetime
- 2003-07-18 AR AR20030102587A patent/AR040500A1/es active IP Right Grant
- 2003-07-18 IL IL16612903A patent/IL166129A0/xx active IP Right Grant
- 2003-07-18 RU RU2005104818/04A patent/RU2005104818A/ru not_active Application Discontinuation
- 2003-07-18 DK DK03765881.2T patent/DK1534290T3/da active
- 2003-07-18 AT AT03765754T patent/ATE505471T1/de not_active IP Right Cessation
- 2003-07-18 DE DE60336732T patent/DE60336732D1/de not_active Expired - Lifetime
- 2003-07-18 SI SI200332120T patent/SI1534290T1/sl unknown
- 2003-07-21 PE PE2003000721A patent/PE20040680A1/es not_active Application Discontinuation
2005
- 2005-01-03 IL IL166129A patent/IL166129A/en unknown
- 2005-01-06 NO NO20050072A patent/NO330132B1/no not_active IP Right Cessation
- 2005-01-11 IL IL16623205A patent/IL166232A0/xx unknown
- 2005-01-12 IS IS7646A patent/IS7646A/is unknown
- 2005-01-12 IS IS7647A patent/IS2880B/is unknown
- 2005-01-13 US US11/035,248 patent/US7265113B2/en not_active Expired - Lifetime
- 2005-01-19 CO CO05003967A patent/CO5680407A2/es active IP Right Grant
- 2005-01-25 NO NO20050417A patent/NO20050417L/no not_active Application Discontinuation
- 2005-08-29 US US11/214,267 patent/US20060058304A1/en not_active Abandoned
2007
- 2007-08-02 US US11/832,976 patent/US7521450B2/en not_active Expired - Lifetime
2009
- 2009-03-06 US US12/399,429 patent/US7820814B2/en not_active Expired - Lifetime
2012
- 2012-03-14 CY CY20121100271T patent/CY1112628T1/el unknown

Also Published As

Publication number	Publication date
AU2003254088A1 (en)	2004-02-09
ES2377963T3 (es)	2012-04-03
DK1534290T3 (da)	2012-04-10
US20090170853A1 (en)	2009-07-02
US20060058304A1 (en)	2006-03-16
AU2003254088B2 (en)	2008-07-17
JP2005538990A (ja)	2005-12-22
US7265113B2 (en)	2007-09-04
BRPI0312940B1 (pt)	2019-07-23
US7820814B2 (en)	2010-10-26
US20040072832A1 (en)	2004-04-15
JP4361485B2 (ja)	2009-11-11
EP1539763A1 (en)	2005-06-15
EP1539763B1 (en)	2011-04-13
EP2280012A3 (en)	2011-05-18
MXPA05000716A (es)	2005-04-08
PL216663B1 (pl)	2014-04-30
RS20050041A (sr)	2007-06-04
HRP20050059B8 (hr)	2016-03-25
US6869952B2 (en)	2005-03-22
WO2004009784A2 (en)	2004-01-29
HK1072545A1 (en)	2005-09-02
CN101880283B (zh)	2012-07-18
HRP20050058A2 (en)	2005-08-31
RU2005104818A (ru)	2005-07-20
WO2004009784A3 (en)	2004-04-22
PL375352A1 (en)	2005-11-28
ATE537843T1 (de)	2012-01-15
ATE505471T1 (de)	2011-04-15
RS52325B (sr)	2012-12-31
EP1534290B1 (en)	2011-12-21
AU2003254017A1 (en)	2004-02-09
KR20080095906A (ko)	2008-10-29
PT1534290E (pt)	2012-03-05
CO5680407A2 (es)	2006-09-29
BR0312940A (pt)	2005-06-21
US7521450B2 (en)	2009-04-21
HRP20050059B1 (hr)	2015-02-27
RU2331642C2 (ru)	2008-08-20
IS7646A (is)	2005-01-12
CN1315833C (zh)	2007-05-16
BRPI0312940B8 (2)	2021-05-25
PL375389A1 (en)	2005-11-28
CA2492665A1 (en)	2004-01-29
NZ537523A (en)	2007-08-31
IS7647A (is)	2005-01-12
IL166129A (en)	2015-04-30
EP2280012A2 (en)	2011-02-02
TWI329112B (en)	2010-08-21
GEP20074124B (en)	2007-06-11
IL166232A0 (en)	2006-01-15
CN1681508A (zh)	2005-10-12
EP1539763A4 (en)	2007-08-01
GEP20074213B (en)	2007-10-10
KR100901939B1 (ko)	2009-06-10
HRP20050059A2 (en)	2005-04-30
EP1534290A4 (en)	2006-11-29
JP2005538989A (ja)	2005-12-22
US6969717B2 (en)	2005-11-29
IL166129A0 (en)	2006-01-15
MXPA05000715A (es)	2006-02-22
NO20050072L (no)	2005-02-03
US20050124621A1 (en)	2005-06-09
CN101880283A (zh)	2010-11-10
WO2004009601A1 (en)	2004-01-29
TW200412973A (en)	2004-08-01
RS20050042A (sr)	2007-06-04
MY134848A (en)	2007-12-31
UA82846C2 (en)	2008-05-26
CN1681508B (zh)	2010-10-06
NO20050417L (no)	2005-02-17
PE20040680A1 (es)	2004-10-08
AR040500A1 (es)	2005-04-06
US20040063707A1 (en)	2004-04-01
CA2492804C (en)	2009-06-23
SI1534290T1 (sl)	2012-05-31
NO330132B1 (no)	2011-02-21
CA2492804A1 (en)	2004-01-29
US20070299075A1 (en)	2007-12-27
CN1681818A (zh)	2005-10-12
IS2880B (is)	2014-05-15
BR0312801A (pt)	2007-06-26
RU2005104422A (ru)	2005-08-10
DE60336732D1 (de)	2011-05-26
EP1534290A2 (en)	2005-06-01
CY1112628T1 (el)	2016-02-10

Legal Events

Date	Code	Title	Description
2009-02-18	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090217
2009-05-19	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090518
2009-05-21	RD03	Notification of appointment of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090520
2009-05-21	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090520
2009-06-24	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090623
2009-07-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090709
2009-08-20	TRDD	Decision of grant or rejection written
2009-08-26	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090825
2009-08-27	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2009-09-28	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090916
2009-10-02	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20121002 Year of fee payment: 3
2009-10-02	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2012-10-02	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20131002 Year of fee payment: 4
2013-10-08	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2014-10-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-10-02	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP4381978B2 (ja)	2009-12-09	アザインドールキナーゼインヒビター
US6951859B2 (en)	2005-10-04	Pyrrolotriazine kinase inhibitors
US7244733B2 (en)	2007-07-17	Pyrrolotriazine inhibitors of kinases
US6933386B2 (en)	2005-08-23	Process for preparing certain pyrrolotriazine compounds
US7102002B2 (en)	2006-09-05	Pyrrolotriazine kinase inhibitors
ES2362421T3 (es)	2011-07-05	Inhibidores de azaindol de la quinasa.
KR20050019903A (ko)	2005-03-03	아자인돌 키나아제 억제제
HK1072545B (en)	2012-06-08	Novel inhibitors of kinases